flowchart TB
subgraph G["GLP-1"]
direction LR
g_brain["Brain<br/>appetite↓, satiety↑<br/>nausea"]
g_st["Stomach<br/>delayed gastric emptying"]
g_heart["Cardiovascular<br/>heart rate↑<br/>effect on atherosclerosis?"]
g_kid["Kidney<br/>Na excretion↑"]
end
subgraph P["GIP"]
direction LR
p_fat["Adipose tissue<br/>lipid uptake↑<br/>blood flow↑"]
p_brain["Brain<br/>appetite↓?<br/>nausea↓?"]
p_bone["Bone<br/>bone resorption↓"]
end
5 Extrapancreatic Actions: Brain, Stomach, Fat, Cardiovascular
The main reason GLP-1 receptor agonists attracted attention as “weight-loss drugs” is their action outside the pancreas, especially appetite suppression via the brain. This chapter organizes the extrapancreatic actions organ by organ.
5.1 The big picture
5.2 Brain: regulation of appetite
5.2.1 How does GLP-1 reach the brain?
There are thought to be three main routes by which circulating GLP-1 and GLP-1RAs act on the brain.
- Vagal afferent fibers: GLP-1R on vagal nerve endings in the gut and around the portal vein is stimulated, and the information is conveyed to the nucleus of the solitary tract (NTS) in the brainstem (thought to be the main route for physiological GLP-1)
- Sites where the blood–brain barrier is weak (circumventricular organs): circulating peptides can directly reach the area postrema (AP) in the brainstem and parts of the arcuate nucleus (ARC) of the hypothalamus
- GLP-1 made in the brain: the NTS contains GLP-1-producing neurons (PPG neurons that express proglucagon), which project to various brain regions
Large fatty-acid-modified GLP-1RAs (such as semaglutide) cannot freely cross the blood–brain barrier. Animal studies suggest that these drugs mainly reach circumventricular organs such as the area postrema and the arcuate nucleus, and from there secondarily engage appetite-related neural circuits.
5.2.2 Circuits that suppress appetite
flowchart LR RA["GLP-1 / GLP-1RA"] --> AP["Area postrema (AP)<br/>Nucleus of the solitary tract (NTS)"] RA --> ARC["Hypothalamic arcuate nucleus (ARC)"] ARC --> POMC["POMC/CART neurons↑<br/>(appetite suppression)"] ARC --> AgRP["NPY/AgRP neurons↓<br/>(suppressing appetite stimulation)"] AP --> PBN["Parabrachial nucleus (PBN)"] PBN --> Sat["Satiety↑, food intake↓"] AP --> Nau["Nausea, vomiting"] POMC --> Sat AgRP --> Sat RA --> Rew["Reward system (mesolimbic)<br/>craving for high-fat foods etc.↓"]
- Hypothalamus (arcuate nucleus): activates appetite-suppressing neurons (POMC/CART) and inhibits appetite-stimulating neurons (NPY/AgRP)
- Brainstem (area postrema, NTS): processes satiety signals. On the other hand, this is also the center for nausea and vomiting, and is thought to be one cause of the gastrointestinal side effects of GLP-1RAs
- Reward system: an action that reduces “wanting” for high-fat, high-carbohydrate foods has also been reported
5.2.3 Actions of GIP in the brain: many mysteries
GIPR is also expressed in the hypothalamus and area postrema. Animal studies have yielded the following findings, but their significance in humans is still under investigation.
- Central GIPR stimulation reduces food intake (additively with GLP-1R agonism)
- Via GIPR-expressing neurons in the area postrema (mainly inhibitory GABA neurons), it may alleviate nausea and vomiting caused by GLP-1RAs
If this holds in humans as well, a dual GIP/GLP-1 agonist could “deliver more action than GLP-1 alone without increasing nausea”, which is one of the hypotheses explaining the strong weight-loss effect of tirzepatide.
5.3 Stomach: delayed gastric emptying
GLP-1 delays gastric emptying (an action mediated by the vagus nerve).
- Food is sent to the intestine slowly → the postprandial rise in blood glucose is flattened
- Food stays in the stomach longer → satiety lasts
- On the other hand, it is also one cause of side effects such as nausea and bloating
It is known that the gastric-emptying delay weakens with continuous stimulation (tachyphylaxis).
- Short-acting (exenatide twice daily, lixisenatide): gastric-emptying delay tends to be preserved → lowers postprandial glucose well
- Long-acting (liraglutide, semaglutide, etc.): gastric-emptying delay weakens → mainly lowers fasting glucose (glucagon suppression, insulin secretion)
This action is clinically important as well; caution is required regarding the risk of aspiration before general anesthesia or endoscopy and effects on the absorption of oral drugs.
5.4 Adipose tissue: the main extrapancreatic target of GIP
GIPR is highly expressed in adipocytes, and GIP acts on adipose tissue as follows.
- Increases blood flow to adipose tissue
- Increases the activity of lipoprotein lipase (LPL), driving the uptake of postprandial triglycerides into adipose tissue
- Promotes fat synthesis and storage in the presence of insulin
Physiologically, by properly “storing away” postprandial lipids in subcutaneous fat, it is thought to have a “lipid buffering” action that prevents lipids from flowing into places where fat should not accumulate (ectopic fat), such as the liver and muscle.
Because GIPR-deficient mice resist obesity even on a high-fat diet, GIP was long considered an “obesity-promoting hormone”, and there was even the idea that blocking GIPR might reduce body weight. On the other hand, tirzepatide activates GIPR and causes substantial weight loss. This seemingly contradictory situation is called the “GIP paradox” (Chapter 6).
5.5 Cardiovascular system and kidney
5.5.1 GLP-1
- Increased heart rate: a common action of GLP-1RAs (a few beats/min). Thought to be mediated by GLP-1R in the sinoatrial node and by the autonomic nervous system
- Lowered blood pressure: a slight decrease
- Reduction of cardiovascular events: several large trials in patients with type 2 diabetes (LEADER, SUSTAIN-6, REWIND, etc.) showed a reduction in major adverse cardiovascular events (MACE). In the SELECT trial, in people with obesity (without diabetes) and cardiovascular disease, semaglutide also reduced MACE by about 20%
- Kidney: natriuretic action. In the FLOW trial, semaglutide reduced a composite kidney endpoint by about 24% in patients with type 2 diabetes and chronic kidney disease
The mechanisms of the cardiovascular and renal protection cannot be fully explained by improvements in body weight, blood glucose, blood pressure, and lipids alone; anti-inflammatory actions and direct effects on atherosclerosis are also discussed, but not yet established.
5.5.2 GIP
- GIPR is barely expressed in the heart
- Indirect effects through actions on blood vessels and adipose tissue are possible, but their clinical significance is still being evaluated
5.6 Bone
- GIP suppresses bone resorption (involved in the fall of bone-resorption markers after meals)
- The effect on bone loss accompanying weight loss is one of the points of interest in long-term use of GIP/GLP-1 agonists
5.7 Summary
| Organ | GLP-1 | GIP |
|---|---|---|
| Brain | Appetite↓ (hypothalamus, brainstem), nausea | Appetite↓?, nausea↓? (mainly animal data) |
| Stomach | Delayed gastric emptying (attenuated with long-acting agents) | Almost none |
| Adipose tissue | Almost none | Lipid uptake↑, blood flow↑ (lipid buffering) |
| Cardiovascular | Heart rate↑, MACE↓ (clinical trials) | Much is unknown |
| Kidney | Natriuresis, kidney events↓ (clinical trials) | Much is unknown |
| Bone | Bone resorption↓ |